00:29 , Oct 20, 2017 |  BC Week In Review  |  Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
20:21 , Oct 17, 2017 |  BC Extra  |  Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

University of Michigan, Kura Oncology deal

Last December, the university granted Kura exclusive, worldwide rights to a class of preclinical small molecule inhibitors targeting menin-MLL fusion oncogene, including MI-463 and MI-503. Preclinical data published in Cancer Cell and...